Navigation Links
NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009
Date:3/2/2009

ANN ARBOR, Mich., March 2 /PRNewswire/ -- NanoBio Corp. announced today that it will present compelling new data highlighting key clinical and preclinical milestones in the development of its novel topical treatments for herpes labialis, onychomycosis and tinea capitis. The new data will be delivered in five presentations during the 2009 meeting of the American Academy of Dermatology in San Francisco, March 6-9, 2009.

In addition to the oral poster presentations listed below, the presentations will be available electronically at the kiosks provided by the AAD during the conference. NanoBio will also sponsor corporate booth # 5284, where information on the company's development programs for acne, herpes and antifungal products will be available.

Oral Poster Presentations

Saturday, March 7, 2009 -- Center 3

Poster # P2411, 10:20 a.m. -- Antifungal Activity and Mechanism of Action of NB-002, a Novel Topical Antifungal, Against the Major Pathogens of Onychomycosis

Poster # P2423, 12:20 p.m. -- Antifungal Activity of NB-002, a Topical Nanoemulsion, Against Rare Fungal Pathogens of Onychomycosis

Poster # P2505, 2:00 p.m. -- Investigator Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis

Poster # P2517, 4:00 p.m. -- Safety, Tolerability and Pharmacokinetics of Topical NB-001 (0.1%, 0.3% and 0.5%) for the Treatment of Recurrent Herpes Labialis

Sunday, March 8, 2009 - Center 1

Poster # P2114, 10:40 a.m. -- A Randomized, Double-Blind, Vehicle-Controlled Trial of Novel Topical Antifungal Nanoemulsion (NB-002) in Subjects With Distal Subungual Onychomycosis

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.


'/>"/>
SOURCE NanoBio Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria
2. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
3. NanoBio Wins 2007 Michigan Innovation Award
4. MedThink Communications Retained by NanoBio Corporation
5. MHA Announces: Launch of New Website
6. National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs
7. Lilly Announces Leadership Changes
8. Availity Announces Support of Project SwipeIT
9. The Vitality Group Announces Expansion to Board of Directors
10. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
11. Boston Scientific Announces Election Of John Sununu To Its Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: